Correspondence 0001104659-23-014964 from CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738) (CASIF)

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)
Date: Feb. 9, 2023 · CIK: 0001962738 · Accession: 0001104659-23-014964

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-269479

Date

February 9, 2023

Author

Form

CORRESP

Company

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)

Letter

VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Washington, D.C. 20549 Re: CASI Pharmaceuticals Holdings, Inc. Registration Statement on Form F-4, as amended File No. 333-269479

Dear Mr. Gorsky:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), CASI Pharmaceuticals Holdings, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form F-4 (File No. 333-269479) be accelerated by the Securities and Exchange Commission to 4:00 p.m., Washington D.C. time on Monday, February 13, 2023, or as soon thereafter as may be practicable.

In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Please contact Rui Zhang, at 617-945-6381 or ruiz@casipharmaceuticals.com if you have any questions. Thank you very much.

[Signature page follows]

Sincerely,
CASI Pharmaceuticals Holdings, Inc.

Show Raw Text

CORRESP
1
filename1.htm

CASI PHARMACEUTICALS HOLDINGS, INC.

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road Chaoyang District

Beijing, 100025

People’s Republic of China

February 9, 2023

VIA EDGAR

Mr. Joshua Gorsky

Division of Corporation Finance

Office of Life Sciences

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

    Re:
    CASI Pharmaceuticals Holdings, Inc.

Registration Statement on Form F-4, as amended

File No. 333-269479

Dear Mr.
Gorsky:

Pursuant to Rule 461 under the Securities Act of
1933, as amended (the “Act”), CASI Pharmaceuticals Holdings, Inc. (the “Company”) hereby requests that the effective
date of the Company’s Registration Statement on Form F-4 (File No. 333-269479) be accelerated by the Securities and Exchange Commission
to 4:00 p.m., Washington D.C. time on Monday, February 13, 2023, or as soon thereafter as may be practicable.

In making this acceleration request, the Company
acknowledges that it is aware of its responsibilities under the Act.

Please contact Rui Zhang, at 617-945-6381 or ruiz@casipharmaceuticals.com
if you have any questions. Thank you very much.

[Signature page follows]

    Sincerely,

    CASI Pharmaceuticals Holdings, Inc.

    By:
    /s/ Kun Qian

    Name:
    Kun Qian

    Title:
    Principal Executive Officer

SecProbe.io